Capital International Investors Buys 67,808 Shares of BeOne Medicines Ltd. – Sponsored ADR $ONC

Capital International Investors increased its stake in shares of BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) by 1.3% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 5,113,866 shares of the company’s stock after acquiring an additional 67,808 shares during the period. Capital International Investors’ holdings in BeOne Medicines were worth $1,553,909,000 as of its most recent filing with the SEC.

A number of other institutional investors have also made changes to their positions in the stock. Signaturefd LLC lifted its holdings in BeOne Medicines by 10.7% in the 4th quarter. Signaturefd LLC now owns 340 shares of the company’s stock worth $103,000 after purchasing an additional 33 shares during the last quarter. Farther Finance Advisors LLC raised its position in shares of BeOne Medicines by 21.8% in the fourth quarter. Farther Finance Advisors LLC now owns 218 shares of the company’s stock valued at $66,000 after purchasing an additional 39 shares during the period. CWM LLC raised its position in shares of BeOne Medicines by 32.8% in the fourth quarter. CWM LLC now owns 158 shares of the company’s stock valued at $48,000 after purchasing an additional 39 shares during the period. Benjamin Edwards Inc. lifted its stake in shares of BeOne Medicines by 8.0% in the fourth quarter. Benjamin Edwards Inc. now owns 690 shares of the company’s stock worth $210,000 after buying an additional 51 shares during the last quarter. Finally, Venturi Wealth Management LLC boosted its holdings in shares of BeOne Medicines by 3.7% during the 4th quarter. Venturi Wealth Management LLC now owns 1,602 shares of the company’s stock worth $487,000 after buying an additional 57 shares during the period. 48.55% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

ONC has been the topic of a number of research analyst reports. Jefferies Financial Group lowered shares of BeOne Medicines from a “buy” rating to a “hold” rating and lowered their target price for the company from $420.00 to $290.00 in a research note on Monday, March 16th. Leerink Partners upped their price target on shares of BeOne Medicines from $364.00 to $367.00 and gave the company an “outperform” rating in a report on Friday, May 15th. Truist Financial reaffirmed a “buy” rating and issued a $413.00 price target (up from $411.00) on shares of BeOne Medicines in a research report on Thursday, May 7th. Wolfe Research assumed coverage on BeOne Medicines in a research report on Friday, March 27th. They set an “outperform” rating and a $340.00 price objective for the company. Finally, Guggenheim increased their target price on BeOne Medicines from $410.00 to $420.00 and gave the company a “buy” rating in a research note on Thursday, May 7th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $390.00.

Insider Transactions at BeOne Medicines

In related news, Director Corazon (Corsee) D. Sanders sold 212 shares of the company’s stock in a transaction on Friday, May 22nd. The stock was sold at an average price of $309.59, for a total value of $65,633.08. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Margaret Dugan sold 212 shares of the firm’s stock in a transaction on Friday, May 22nd. The stock was sold at an average price of $309.60, for a total value of $65,635.20. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders sold 1,641 shares of company stock worth $505,791. Insiders own 6.19% of the company’s stock.

BeOne Medicines Price Performance

Shares of BeOne Medicines stock opened at $270.10 on Friday. The company has a debt-to-equity ratio of 0.20, a current ratio of 3.64 and a quick ratio of 3.27. The company has a market cap of $29.64 billion, a PE ratio of 60.43 and a beta of 0.49. The firm has a fifty day moving average price of $301.86 and a two-hundred day moving average price of $317.87. BeOne Medicines Ltd. – Sponsored ADR has a fifty-two week low of $239.25 and a fifty-two week high of $385.22.

BeOne Medicines (NASDAQ:ONC) last posted its quarterly earnings data on Wednesday, April 1st. The company reported $0.25 earnings per share (EPS) for the quarter. BeOne Medicines had a net margin of 8.94% and a return on equity of 12.06%. The company had revenue of $1.51 billion for the quarter. Analysts expect that BeOne Medicines Ltd. – Sponsored ADR will post 6.14 EPS for the current year.

BeOne Medicines Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.